Single-Dose HPV Vaccine Efficacy
A single dose of HPV vaccine provides highly effective and durable protection against HPV infection, with efficacy exceeding 80% and remaining stable for over a decade, though completing the recommended series remains the standard of care.
Evidence for Single-Dose Efficacy
The most compelling recent evidence comes from a 2026 randomized crossover trial in Kenya, which demonstrated that single-dose HPV vaccination achieved 99.3% efficacy (95% CI: 96.2-99.9%) against persistent HPV 16/18 infections and 98.9% efficacy (95% CI: 94.9-99.8%) against HPV 16/18/31/33/45/52/58 infections over 54 months of follow-up 1. Critically, the durability analysis showed no meaningful decline in protection over time.
Additional long-term data from the Costa Rica Vaccine Trial showed that after more than 11 years of follow-up, single-dose vaccine efficacy against HPV 16/18 infection remained 82.1% (95% CI: 40.2-97.0%), comparable to the 80.2% efficacy seen with three doses 2. Antibody levels remained stable between years 4 and 11, though quantitatively lower than multi-dose recipients.
A 2026 real-world effectiveness study from Thailand demonstrated 91.0% effectiveness (95% CI: 33.4-98.8) against high-risk HPV types among young women with >5 years since vaccination, with similar protection across age groups 9-18 years 3.
Immunogenicity and Antibody Response
While single-dose vaccination generates lower geometric mean antibody concentrations compared to multi-dose schedules (ranging from 2.17 to 176 EU/mL versus 7.92 to 1045.37 EU/mL for three doses), these levels remain protective 4. The antibody titers do not decline qualitatively over time, suggesting durable immune memory 2.
Current Guideline Recommendations
The existing ACIP guidelines from 2007 specify a 3-dose schedule (at 0,2, and 6 months) and do not address single-dose efficacy, as this evidence was not available at that time 5. These guidelines state that if the series is interrupted after the first dose, the second dose should be administered as soon as possible, with the series not needing to be restarted 5.
However, the WHO proposed a single-dose regimen in 2022 as an effective strategy, representing a major shift in global vaccination policy 6. This recommendation was based on accumulating evidence of single-dose durability and aims to improve public health accessibility.
Clinical Approach for Your Patient
For the patient who received only one dose:
- Reassure them that they have substantial protection (>80% efficacy) against HPV 16/18 and related cancer-causing types
- Strongly recommend completing the series to achieve optimal protection, as this remains the FDA-approved regimen and current U.S. standard of care
- Explain that while single-dose efficacy is high, the second dose should be given as soon as possible, with at least 12 weeks between the second and any subsequent third dose 5
- The series does not need to be restarted regardless of the time elapsed 5
Important caveats:
- Continue cervical cancer screening according to standard guidelines, as the vaccine covers approximately 70% of cervical cancer-causing HPV types with the quadrivalent vaccine 5
- Single-dose protection does not eliminate the need for safe sexual practices and STI prevention counseling 7
- The patient likely has protection against HPV types they were not already exposed to, even if sexually active 5
Dosing intervals if completing the series:
- Minimum interval between doses 1 and 2: 4 weeks
- Minimum interval between doses 2 and 3: 12 weeks 5
The evidence strongly supports that your patient has meaningful protection from their single dose, but completing the series remains the evidence-based recommendation to maximize long-term protection and align with current FDA licensure and ACIP guidelines in the United States.